Dr. Shah on the Safety of a Novel Dual-Targeted CAR T-Cell Therapy in Non-Hodgkin Lymphoma

Video

Nirav Shah, MD, MCW, discusses the safety profile of an anti-CD20/anti-CD19 CAR T-cell therapy under investigation in the treatment of patients with non-Hodgkin lymphoma.

Nirav Shah, MD, MCW, an associate professor at the Medical College of Wisconsin, discusses the safety profile of an anti-CD20/anti-CD19 CAR T-cell therapy under investigation in the treatment of patients with non-Hodgkin lymphoma.

The safety of the CAR T-cell product was examined in a phase 1 study that launched in 2017, according to Shah. When the trial began, it was one of the first studies to examine a dual-targeted agent in this patient population. Because of this, it was very important to demonstrate the product's safety, Shah explains, as there are concerns that targeting more than 1 B-cell antigen could result in increased toxicities like cytokine release syndrome (CRS) and neurotoxicity.

The CAR T-cell therapy was found to be safe, Shah says. The incidence of CRS and neurotoxicity were low and no patients died as a result of undergoing treatment. Additionally, the adverse effects reported in patients were found to be reversible. Investigators were able to identify a safe and efficacious dose of 2.5 × 106 cells/kg that will be further evaluated in a larger phase 2 study. With this effort, investigators hope to further demonstrate the efficacy of the product.

Although the agent has already shown a promising response signal, the phase 1 study was comprised of a smaller patient population, Shah explains. The phase 2 study will offer the opportunity to evaluate the recommended phase 2 dose of the agent in a larger patient population, Shah concludes.

Recent Videos
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Sarah Hein, PhD, the chief executive officer and cofounder of March Biosciences
Brian Kim, MBA, the chief executive officer of Mission Bio
Peter Cook, PhD, a senior research scientist at Seattle Children’s Research Institute
Nicholas Giovannone, PhD, a senior principal scientist at Regeneron
Related Content
© 2025 MJH Life Sciences

All rights reserved.